Opinion

Video

Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

Author(s):

Catherine C. Coombs, MDMatthew S. Davids, MD, MMSc

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.

  1. Dr Davids: What is your general approach to navigating available treatment options in patients with newly diagnosed CLL?
    • In which patients do you consider fixed duration vs continuous BTKi therapy?
    • How do the presence of high-risk features (del17p, TP53 mutations) influence your treatment decision?
Related Videos
Alexey Danilov, MD, PhD
5 KOLs are featured in this program
5 KOLs are featured in this program
5 KOLs are featured in this panel.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Paolo Ghia, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Related Content
Consuelo Bertossi, MD, of University Hospital Ulm in Germany
June 18th 2024

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Stephen Opat, of Monash Health
June 17th 2024

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

William Wierda, MD, PhD
June 17th 2024

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL

Adam Kittai, MD, of The Ohio State University
June 16th 2024

CD19-Directed CAR T-Cell Therapy Demonstrates Clinical Efficacy in Richter Transformation